Drug · CHEMBL762
OXYMETAZOLINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. OXYMETAZOLINE. Drugs and targets, record CHEMBL762. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL762
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets6
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha | Adrenergic receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/148 |
| ADRA1B | Adrenergic receptor alpha | Adrenergic receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/147 |
| ADRA1D | Adrenergic receptor alpha | Adrenergic receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/146 |
| ADRA2A | Adrenergic receptor alpha | Adrenergic receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/150 |
| ADRA2B | Adrenergic receptor alpha | Adrenergic receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/151 |
| ADRA2C | Adrenergic receptor alpha | Adrenergic receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/152 |
Source ChEMBL
Diseases14
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 14Source Open Targets
See all 14 diseasesTrials40
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00552110 | Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500) | Phase 2 | 707 | 2009-07-08 | oxymetazoline | Its name | ClinicalTrials.gov |
| NCT02095158 | A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea | Phase 3 | 440 | 2016-09-21 | oxymetazoline | Its name | ClinicalTrials.gov |
| NCT02285634 | The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial. | 68 | 2018-10-02 | oxymetazoline | Its name | ClinicalTrials.gov | |
| NCT00584987 | Intranasal Steroids and Oxymetazoline in Allergic Rhinitis | Phase 4 | 64 | 2013-12-17 | oxymetazoline | Its name | ClinicalTrials.gov |
| NCT01847131 | Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction | Phase 4 | 50 | 2015-01-05 | oxymetazoline | Its name | ClinicalTrials.gov |
| NCT03352323 | An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea | Phase 3 | 50 | 2021-01-05 | oxymetazoline | Its name | ClinicalTrials.gov |
| NCT02453841 | Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption | 30 | 2018-09-18 | oxymetazoline | Its name | ClinicalTrials.gov | |
| NCT01660893 | Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth | Phase 3 | 26 | 2017-09-05 | oxymetazoline | Its name | ClinicalTrials.gov |
| NCT03228914 | Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery | Phase 4 | 20 | 2021-01-13 | oxymetazoline | Its name | ClinicalTrials.gov |
| NCT05348148 | Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis | 450 | oxymetazoline | Its name | ClinicalTrials.gov |
1 to 10 of 40
See all 40 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oxymetazoline vs Placebo: The Numbers of Subjects Who Developed Rhinitis Medicamentosa After Using Oxymetazoline | 0 of 25 | 0 of 25 | 50 | NCT01847131 | Trial comparisons |
| Oxymetazoline vs Placebo: serious adverse events | 0 of 25 | 0 of 25 | 50 | NCT01847131 | Trial comparisons |
| Oxymetazoline vs Epinephrine: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT03228914 | Trial comparisons |
| Oxymetazoline vs Epinephrine: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT03228914 | Trial comparisons |
Papers from its trials53
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL762
GET https://conductscience.org/api/drugs/v1/CHEMBL762/trials?page=2